Actively Recruiting
Evaluation of Ravulizumab for Chinese Adults With Neuromyelitis Optica Spectrum Disorder A Phase 3b Open-Label Study Assessing Efficacy, Safety, and Immune Response
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-09-11
19
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of ravulizumab for treating Chinese adults diagnosed with neuromyelitis optica spectrum disorder NMOSD who test positive for anti-aquaporin-4 antibodies. The study aims to confirm how effective and safe ravulizumab is, along with understanding its pharmacokinetics, pharmacodynamics, and immunogenicity in this group. Participants will receive a weight-based loading dose of ravulizumab through intravenous infusion on the first day, followed by maintenance doses given every eight weeks up to 50 weeks. This is an open-label, single-group, phase 3b study without a placebo group. During the study, participants will be monitored regularly for disease relapse rates and changes in disability scores, quality of life, and adverse events. Blood samples will be collected to measure drug levels and immune responses. The total participation period lasts up to approximately 50 weeks, with ongoing safety and efficacy assessments throughout.
CONDITIONS
Brief Title
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here